MDXG reports Q1 2026 results on April 30 against a backdrop of unusually bullish options positioning — a sharp reversal from the defensive stance that dominated for weeks.
The options signal is the standout heading into this print. The put/call ratio has collapsed to 0.71, nearly two standard deviations below its 20-day average of 1.27 — making this one of the most call-heavy readings of the past year. Just two weeks ago, the PCR was running above 1.49. That rotation from heavy put protection to call dominance is abrupt, and it coincides with a stock that has fallen 19% in a month to $3.085 and dropped another 9.3% on April 29 alone.
That price slide complicates the bullish options read. The stock is materially weaker than most of its correlated peers heading into the session — ENTA added 3.2% on the day and EBS rose 2.5%, while MDXG fell sharply. The peer divergence sharpens the question the earnings print must answer: is the selloff a valuation reset ahead of a solid quarter, or is it anticipating a guidance cut?
The short-selling community is not pressing its advantage. Short interest is a modest 5% of the free float, and availability in the lending market remains loose. Cost to borrow is just 0.80%, up sharply on the week but still low in absolute terms — no sign of a borrow squeeze. The ORTEX short score of 47 is mid-range and has been drifting lower over the past two weeks, suggesting short sellers are not adding aggression into the print.
Analysts are largely still constructive but have spent recent months walking down their targets. Citizens and Craig-Hallum both trimmed price targets to $7 in mid-to-late April while keeping positive ratings — the consensus mean stands at $8.20 against a stock now trading at $3.09, a gap that reflects how much ground has been lost since the start of the year. Bulls point to strong surgical-segment momentum and a revenue growth trajectory that reached 13% year-over-year last quarter. Bears flag gross margin compression — down from 83% to roughly 81% — and the ever-present risk that CMS reimbursement changes could hit the wound-care business harder than current guidance assumes.
The Q1 print will test whether the company can sustain double-digit revenue growth and hold adjusted EBITDA margins above 20% — and whether analysts' $7-plus targets reflect a realistic near-term path, or a hope that the stock has simply fallen too far.
See the live data behind this article on ORTEX.
Open MDXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
